Decreased uptake after fractionated ablative doses of iodine-131

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 2, 2005, Pages 167-173

  Wu, Hurng Sheng ^a   Hseu, Huey Herng ^b   Lin, Wan Yu ^b   Wang, Shyh Jen ^b   Liu, Yao Chi ^c  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Decreased uptake; Fractionated doses; Thyroid cancer 131I ablation; Thyroid stunning

Indexed keywords

IODINE 131;

ADULT; AGED; ARTICLE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; HUMAN; IMAGING SYSTEM; IODINE 131 UPTAKE TEST; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NECK INJURY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; THYROID CANCER; WHOLE BODY SCINTISCANNING;

ADULT; AGED; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; THYROID GLAND; THYROID NEOPLASMS;

EID: 13844292469     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1655-1     Document Type: Article

References (25)

1. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002;12:683-702.
2. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52.
3. de Keizer B, Koppeschaar HP, Zelissen PM, Lips CJ, van Rijk PP, van Dijk A, de Klerk JM. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001; 28:198-202.
4. Arslan N, Ilgan S, Serdengecti M, Ozguven MA, Bayhan H, Okuyucu K, Gulec SA. Post-surgical ablation of thyroid remnants with high-dose I-131 in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001;22:1021-7.
5. 131I dose in differentiated thyroid cancer. Clin Endocrinol 2000;52:765-73.
6. Lin JD, Kao PF, Chao TC. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 1998;71:307-13.
7. Arad E, Flannery K, Wilson GA, O'Mara RE. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med 1990;15:676-7.
8. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol 1951;11:1128-42.
9. Cavalieri RR. Nuclear imaging in the management of thyroid carcinoma. Thyroid 1996;6:485-92.
10. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:242-6.
11. Medvedec M. Thyroid stunning. J Nucl Med 2001;42:1129-31.
12. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000;27:1591-7.
13. 131I. Eur J Nucl Med Mol Imaging 2002;29:1421-7.
14. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507-11.
15. Huic D, Medvedec M, Dodig D, Popovic S, Ivancevic D, Pavlinovic Z, Zuvic M. Radioiodine uptake in thyroid cancer patients. Nucl Med Commun 1996;17:839-42.
16. McDougall IR. 74 MBq radioiodine I-131 dose not prevent uptake of therapeutic doses of I-131 (i.e., it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18:505-12.
17. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39:1546-50.
18. 131I. J Nucl Med 2000;41:1198-202.
19. Coakley AJ. Thyroid stunning. Eur J Nucl Med 1998; 25:203-4.
20. Chopra S, Wastie ML, Chan S, Vincent RM, Przeslak A, Perkins AC, Ubhi CS. Assessment of completeness of thyroid ablation by estimation of neck uptake of I-131 on whole body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 1996;17:687-91.
21. Yeung HW, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000;41:1082-5.
22. Diehl M, Grunwald F. Stunning after tracer dosimetry [letter to editor]. J Nucl Med 2001;7:1129.
23. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
24. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41.
25. Kao CH, Yen TC. Stunning effects after a diagnostic dose of Iodine-131. Nuklearmedizin 1998;37:23-5.